Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946889 | 0.90 | FSCN1 (0.42) | METPDE10AFSCN1PPARGMEN1 | |
| SCHEMBL2949605 | 0.88 | MET (0.39) | METPDE10AFSCN1PPARGMEN1 | |
| SCHEMBL2948096 | 0.87 | PDE10A (0.40) | METPDE10AFSCN1PPARGMEN1 | |
| SCHEMBL5257090 | 0.85 | MET (0.38) | METPDE10AFSCN1PPARGMEN1 | |
| SCHEMBL4806235 | 0.85 | HTR6 (0.42) | METFSCN1 | |
| SCHEMBL2943245 | 0.81 | FSCN1 (0.42) | METPDE10AFSCN1PPARGPTGDR2 | |
| SCHEMBL4799406 | 0.81 | LMNA (0.42) | METPDE10AFSCN1MEN1KMT2A | |
| SCHEMBL1684119 | 0.81 | PPARG (0.51) | METPPARG | |
| SCHEMBL4811995 | 0.80 | FSCN1 (0.39) | METPDE10AFSCN1PPARGPTGDR2 | |
| SCHEMBL4804475 | 0.80 | HDAC6 (0.37) | METFSCN1PPARGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | MET 4102/4885PDE10A 1453/4885FSCN1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.